1. Phase I and pharmacologic study of irinotecan and amrubicin in advanced non-small cell lung cancer

   • Tomoko Yanaihara
   • Masanori Yokoba
   • Noriyuki Masuda

   Original Article 11 July 2006 Pages: 419 - 427

   

2. Androgen and c-Kit receptors in desmoplastic small round cell tumors resistant to chemotherapy: novel targets for therapy

   • Robert L. Fine
   • Samir S. Shah
   • Gregory Halligan

   Original Article 03 August 2006 Pages: 429 - 437

   

3. Fascaplysin, a selective CDK4 inhibitor, exhibit anti-angiogenic activity in vitro and in vivo

   • Jing Lin
   • Xiao-Jun Yan
   • Hai-Min Chen

   Original Article 01 July 2006 Pages: 439 - 445

   

4. A phase II study of weekly irinotecan as first-line therapy for patients with metastatic pancreatic cancer

   • Hideki Ueno
   • Takuji Okusaka
   • Soh Saitoh

   Original Article 20 July 2006 Pages: 447 - 454

   

5. Effects of mycophenolate mofetil on cisplatin-induced renal dysfunction in rats

   • Sherif Y. Saad
   • Maha M. Arafah
   • Tawfeeg A. Najjar

   Original Article 20 July 2006 Pages: 455 - 460

   

6. Plasma and cerebrospinal fluid pharmacokinetics of pemetrexed after intravenous administration in non-human primates

   • Stacie L. Stapleton
   • Joel M. Reid
   • Susan M. Blaney

   Original Article 20 July 2006 Pages: 461 - 466

   

7. A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors

   • Matthew G. Fury
   • David B. Solit
   • Naiyer A. Rizvi

   Original Article 01 August 2006 Pages: 467 - 475

   

8. Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: part 3. Therapeutic efficacy and safety studies in ovarian cancer xenograft model

   • Harikrishna Devalapally
   • Dinesh Shenoy
   • Mansoor Amiji

   Original Article 22 July 2006 Pages: 477 - 484

   

9. Pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia treated with arsenic trioxide

   • Shinya Fujisawa
   • Ryuzo Ohno
   • Kazunori Ohnishi

   Original Article 26 August 2006 Pages: 485 - 493

   

10. Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia

    • Xianhua Cao
    • Lanyan Fang
    • Duxin Sun

    Original Article 12 August 2006 Pages: 495 - 505

    

11. Clinical evaluation of chemosensitivity testing for patients with unresectable non-small cell lung cancer (NSCLC) using collagen gel droplet embedded culture drug sensitivity test (CD-DST)

    • Masafumi Kawamura
    • Masatoshi Gika
    • Koichi Kobayashi

    Original Article 08 August 2006 Pages: 507 - 513

    

12. Additive antitumor effect of concurrent treatment of 4-hydroxy tamoxifen with 5-fluorouracil but not with doxorubicin in estrogen receptor-positive breast cancer cells

    • Junichi Kurebayashi
    • Mamoru Nukatsuka
    • Hiroshi Sonoo

    Original Article 10 August 2006 Pages: 515 - 525

    

13. Adaphostin cytoxicity in glioblastoma cells is ROS-dependent and is accompanied by upregulation of heme oxygenase-1

    • Jason Long
    • Tejas Manchandia
    • Joya Chandra

    Original Article 19 August 2006 Pages: 527 - 535

    

14. In vitro and in vivo metabolism of paclitaxel poliglumex: identification of metabolites and active proteases

    • Scott A. Shaffer
    • Cassie Baker-Lee
    • Jack W. Singer

    Original Article 19 August 2006 Pages: 537 - 548

    

15. A phase I study of oxaliplatin in combination with gemcitabine: correlation of clinical outcome with gene expression

    • Stephen Shibata
    • Warren Chow
    • James Doroshow

    Original Article 19 October 2006 Pages: 549 - 557

    

16. Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies

    • Sarah A. Holstein
    • Howard R. Knapp
    • Raymond J. Hohl

    Erratum 12 September 2006 Pages: 559 - 559